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Pediatric Mastocytosis Is a Clonal Disease Associated
with D816V and Other Activating c-KIT Mutations
Christine Bodemer1,2,3, Olivier Hermine2,4,5, Fabienne Palme´rini2,6,7, Ying Yang7, Catherine
Grandpeix-Guyodo2, Phillip S. Leventhal8, Smail Hadj-Rabia1,3, Laurent Nasca6,7,
Sophie Georgin-Lavialle2,4, Annick Cohen-Akenine8, Jean-Marie Launay9, Ste´phane Barete2,4,
Fre´de´ric Feger4, Michel Arock4, Benoıˆt Catteau10, Beatrix Sans11, Jean Franc¸ois Stalder12,
Francois Skowron13, Luc Thomas14, Ge´rard Lorette15, Patrice Plantin16, Pierre Bordigoni17,
Olivier Lortholary2,3,18, Yves de Prost1,3, Alain Moussy8, Hagay Sobol6,19,20 and Patrice Dubreuil6,7
Adult mastocytosis is an incurable clonal disease associated with c-KIT mutations, mostly in exon 17 (D816V). In
contrast, pediatric mastocytosis often spontaneously regresses and is considered a reactive disease. Previous studies
on childhood mastocytosis assessed only a few patients and focused primarily on codon 816 mutations, with various
results. In this study, we analyzed the entire c-KIT sequence from cutaneous biopsies of 50 children with mastocytosis
(ages 0–16 years). A mutation of codon 816 (exon 17) was found in 42% of cases, and mutations outside exon 17 were
observed in 44%. Unexpectedly, half of the mutations were located in the fifth Ig loop of c-KIT’s extracellular domain,
which is encoded by exons 8 and 9. All mutations identified in this study were somatic and caused a constitutive
activation of c-KIT. There was no clear phenotype–genotype correlation, no clear relationship between the mutations
and familial versus spontaneous disease, and no significant change in the relative expression of the c-KIT GNNKþ
and GNNK isoforms. These findings strongly support the idea that, although pediatric mastocytosis can
spontaneously regress, it is a clonal disease most commonly associated with activating mutations in c-KIT.
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INTRODUCTION
Mastocytosis is a heterogeneous group of clinical disorders
characterized by the abnormal accumulation of mast cells in
various tissues, especially in the skin and hematopoietic
organs (Valent et al., 2003b; Akin and Metcalfe, 2004).
Mastocytosis usually appears in infancy or early adulthood. In
most pediatric cases, the disease is limited to the skin, but it
can be associated with systemic symptoms due to the release
of mediators from mast cells, even when there is no systemic
infiltration. The typical presentation of childhood-onset
mastocytosis includes cutaneous manifestations (that is,
mastocytoma, urticaria pigmentosa, and, less commonly,
diffuse cutaneous mastocytosis), and it usually has a good
prognosis, with substantial improvement or spontaneous
resolution before puberty (Kiszewski et al., 2004; Ben-Amitai
et al., 2005). In a few cases, particularly in the neonatal
diffuse cutaneous form, the disease can be fatal as a result of
hypovolemic shock, although infrequent, systemic forms can
occur in children. In these cases, the disease may remain
active through adolescence as a systemic adult mastocytosis.
Clinical or biological factors that predict the evolution and
severity of the disease in affected children have not yet been
identified.
In contrast to childhood-onset mastocytosis, adult-onset
mastocytosis often persists for the lifetime of the patient.
Adult-onset mastocytosis is also more likely to be a severe
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and systemic disease involving numerous organs. In some
cases, it is associated with a clonal hematologic non-mast-
cell lineage disease, such as a myelodysplastic or myelo-
proliferative disorder. Adult-onset mastocytosis can also
lead to the rare mast cell leukemia, which carries a high
risk of mortality (Valent et al., 2003a).
It has now been clearly demonstrated that adult mastocy-
tosis is related to the clonal proliferation of mast cells
secondary to a gain of function of the proto-oncogene c-KIT
(Longley et al., 1996, 1999). Thus, in most cases adult
mastocytosis is now considered a clonal myeloproliferative
disorder. The c-KIT gene encodes a type III transmembrane
tyrosine kinase that is the receptor for stem cell factor (SCF)
(Broudy, 1997). The protein possesses an extracellular ligand-
binding domain composed of five Ig-like regions, followed by
a transmembrane domain, a negative regulatory juxtamem-
brane intracellular domain, and a cytoplasmic protein
tyrosine kinase domain split by an insert into adenosine
triphosphate–binding and phosphotransferase regions (Yarden
et al., 1987; Qiu et al., 1988). The two KIT isoforms differ in
the presence or absence of four amino acids (GNNK) in the
juxtamembrane region of the extracellular domain. Impor-
tantly, tyrosine autophosphorylation of the GNNK isoform is
more rapid and gives rise to greater phosphorylation and
activation of MAP kinase than is seen with the GNNKþ
form. Ordinarily, the GNNK form predominates (Caruana
et al., 1999). A variety of mutations have been found in
c-KIT. Although it is not clear how heterogeneity in c-KIT
mutations is involved in adult mastocytosis, it might
account for the diversity of clinical presentations. Most
patients with adult-onset mastocytosis have been reported
to have the D816V mutation. The V560G mutation is also
found but is less frequent. Both the D816V and the V560G
mutations constitutively activate c-KIT, resulting in the
clonal proliferation of mast cells (Longley et al., 2001).
Constitutively activated KIT is involved in other prolifer-
ative disorders, such as in gastrointestinal stromal tumors
(GISTs), in which imatinib mesylate was found to be
effective. In GISTs, most of the c-KIT mutations lie within
the juxtamembrane intracellular domain. The location of
the mutation is important in that the presence of a mutation
in the phosphotransferase domain (D816V mutation) confers
a spontaneous resistance to imatinib mesylate as in most of
adult-onset mastocytosis.
The frequency and role of c-KIT mutations in childhood-
onset mastocytosis and whether it is a clonal disease remain a
matter of debate. A study by Longley et al. (1996) of six
typical pediatric mastocytosis patients found that all lacked
mutations in codon 816 but that three of the six had a
dominant inactivating mutation, K839E. Similarly, Buttner
et al. (1998) reported that of 11 patients with childhood-onset
mastocytosis, none had codon 816 mutations, suggesting that
childhood mastocytosis is a reactive rather than a clonal
disease. In contrast, in more recent studies, Yanagihori et al.
(2005) found missense mutations in codon 816 in 10 of 12
Japanese children with mastocytosis, and Verzijl et al. (2007)
found that 25% of children with urticaria pigmentosa had the
D816V mutation.
Thus, most of the studies on the role of c-KIT mutations in
childhood mastocytosis have focused on codon 816 and
included relatively few patients. In this study, we screened
the entire coding sequence of c-KIT mRNA from cutaneous
lesions of 50 children between 0 and 16 years of age with
sporadic or familial mastocytosis. Overall, 86% of the patients
had mutations in c-KIT. The D816V mutation was present in
35% of the children, including two of four children with a
familial form of the disease. We also found two patients with
a D816Y mutation and one with a D816I mutation. Importantly,
44% of the children had mutations in exons 8, 9, and 11 that
were mutually exclusive of the codon 816 mutations. All the
detected mutations activated the c-KIT tyrosine kinase. Finally,
we did not find any clear phenotype–genotype correlations,
any notable differences in the relative expression of c-KIT
GNNK isoforms, or a clear relationship between the geno-
type and familial versus sporadic forms of the disease. These
findings indicate that, despite the high rate of spontaneous
regression, childhood mastocytosis is most often a clonal
disease associated with activating mutations in c-KIT.
RESULTS
Clinical characteristics of patients
We performed a multicenter study to examine the association
of c-KIT mutations with childhood-onset mastocytosis. The
study included 65 patients with childhood-onset mastocytosis.
The mean age was 7.0±4.7 years. A case report form was
completed for 54 of the 65 patients, and mutation screening
was performed in 50 cases. The total population consisted of
38 (58%) males and 27 (42%) females, with an equal
distribution of the different forms of mastocytosis in males
and females. The type of skin lesion was urticaria pigmentosa
in 80% of the patients, mastocytoma in 11%, and diffuse
cutaneous mastocytosis in 9%. In 13% of cases, another
member of the family also suffered from mastocytosis. Lesions
appeared before 2 years of age in 85% of the patients, between
3 and 9 years in 13%, and around 14 years of age in the
remaining 12%. The overall mean age of onset was 3.0±3.5
years. The serum tryptase levels determined in 17 cases were
within the normal range (o15mg l1) (Table 1). A bone marrow
biopsy was collected from only one case (patient M099)
(Table 1). Our ethics committee prohibited the collection of
blood or additional biopsy samples from the patients except
when necessary for therapeutic decisions. It was possible to
collect a bone marrow biopsy from patient M099 because,
being 16 years old at the time of analysis, he was considered an
adult patient in France. This patient had shown diffuse
cutaneous involvement since birth, along with severe systemic
manifestations, hepatomegaly, splenomegaly, and adenopathy.
Histological analysis of the bone marrow biopsy showed
infiltration by pathological mast cells (410%), confirming
systemic disease.
Analysis of c-KIT codon 816
The D816V mutation of c-KIT, which lies within and activates
the kinase domain, is frequently associated with adult
mastocytosis (Longley et al., 2001). One previous study of
children with mastocytosis did not find this mutation (Longley
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Table 1. Summary of patient characteristics and c-KIT mutation status
c-KIT sequence–RNA1
No. Sex
Type of skin
lesion
Age at
onset
Age at
biopsy
Serum tryptase
(ngml1)
Familial
case Mutation Exon
Exon 10
sequence c-KIT sequence–DNA2
E001 M UP 1 week 3 years 3.2 No D816V 17 M541L ND
E015 M UP 9 months 3 years 4.9 No D816V 17 M541L ND
E033 M UP 2 months 10 years ND No D816V 17 M541L ND
E047 F UP 2 months 2 years ND No D816V 17 M541L ND
E009 F UP Birth 10 years 5 No D816V 17 WT ND
E012 F UP Birth 3 years ND No D816V 17 WT ND
E024 M UP Birth 4 years 14.3 No D816V 17 WT ND
E025 F UP 1 month 3 years ND No D816V 17 WT WT
E027 F UP 2 years 7 years 3.4 Yes D816V 17 WT ND
E031 F UP 9 months 9 years 6.1 No D816V 17 WT WT
E034 M UP 3 months 11 years ND No D816V 17 WT WT
E035 F UP 16 years 18 years ND No D816V 17 WT WT
E036 M UP 4 months 2 years ND No D816V 17 WT ND
E049 M UP 4 months 2 years ND No D816V 17 WT ND
E004 M DCM 3 months 7 years 5.9 No D816V 17 WT ND
M081 M NA Birth 3 years ND No D816V 17 WT ND
M084 M NA Birth 9 years ND Yes D816V 17 WT WT
E006 M NA NA NA ND No D816V 17 WT ND
E018 M UP 5 weeks 5 years ND No D816Y 17 M541L WT
M099 M DCM3 Birth 16 years ND No D816Y 17 WT ND
E010 M DCM Birth 7 years 2.7 No D816I 17 WT ND
E005 M UP Birth 2 years 4 No InsFF419 8 M541L WT
E008 F UP 4 months 8 years 1.4 No D419 8 M541L ND
E050 F UP 4 months 5 months ND No D419 8 M541L ND
E022 F UP 2 months 2 years 4.5 No D419 8 WT ND
E038 M UP 5 months 6 years ND No D419 8 WT WT
E030 M DCM 2 months 3 years 7.2 No D419 8 M541L ND
E026 F NA Birth 9 years 10 No D419 8 M541L WT
E061 F NA Birth 1 year ND No D419 8 WT WT
E011 F MC Birth 4 years ND No D417419InsY 8 WT ND
E017 M MC/UP 3 months/12 months4 6 years ND No C443Y 8 WT WT
E032 F UP 4 m 5 years ND No S476I 9 WT ND
E054 M NA NA NA ND No ITD501502 9 M541L ND
E013 M UP 1 year 10 years ND No ITD501502 9 M541L WT
E002 M UP Birth 1 year ND No ITD502503 9 WT ND
E020 M DCM 1 year 5 years 7.1 No ITD502503 9 WT ND
E041 F MC 2 months 3 years ND No ITD505508 9 WT ND
E007 M UP 7 years 9 years 4.6 No K509I 9 M541L ND
E014 F UP 3 months 1 year 3.9 No K509I 9 WT WT
E040 F UP 1 year 2 years ND No K509I 9 WT ND
E044 M UP 10 months 2 years ND No K509I 9 WT ND
E053 F UP 3 months 2 years ND No K509I 9 WT ND
Table 1 continued on the following page
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et al., 1996; Buttner et al., 1998), although one study found
this mutation in 7% (Longley et al., 1999), another found it in
25% (Verzijl et al., 2007) of patients, and a third found it in
64.3% (Yanagihori et al., 2005). Therefore, we first examined
the frequency of this mutation in our panel of children with
mastocytosis. We found that 29 of the 50 children (58%) had
the wild-type sequence (Asp) at codon 816 (Figure 1 and
Table 1). Eighteen (36%) of the remaining children had the
D816V mutation, and two (4%) had a D816Y mutation,
including the patient diagnosed with systemic mastocytosis.
Also, one patient (2%) had a previously undescribed D816I
mutation. We did not have sequence data from bone marrow
because the collection of bone marrow biopsies from the
children in this study was prohibited by our ethical
committee, except when necessary for therapeutic decisions.
Importantly, bone marrow samples were not needed because
analysis of the cutaneous biopsies was sensitive enough to
detect the mutations.
We next carried out restriction-length polymorphism
analysis to confirm the presence or absence of mutations at
codon 816. The cDNAs generated from the cutaneous biopsy
samples were amplified by PCR using fluorescent primers,
and the resulting amplimers were digested with PleI or
BsmA1, which specifically cut the D816V-containing seq-
uence and the wild-type sequence, respectively. This method
was sensitive enough to detect the mutated allele when it was
present in as few as approximately 2% of the cells in the
sample. The results of this analysis confirmed the presence or
absence of the mutations that had been identified by
sequencing (data not shown).
Identification of mutations in other codons
Because a substantial portion of our patient population (58%)
lacked changes in codon 816, we investigated whether they
had mutations at other sites in c-KIT or whether the technique
was not sufficiently sensitive to detect the D816V mutation in
these cases. We therefore sequenced the entire c-KIT coding
region for all patients lacking the D816V mutation. Five PCR
fragments were amplified covering the entire c-KIT-coding
sequence: nucleotides 1–792 (exons 1–4), 729–1288 (exons
4–7/8), 1197–2121 (exons 7–14), 1934–2517 (exons 13–17/
18), and 2413–2991 (exons 17–21) (Figure 1). Direct
sequencing of these PCR amplimers was carried out for each
patient sample, and identified mutations were confirmed by
performing a new reverse transcription reaction.
Using this method, we identified several new mutations in
c-KIT in our patient population. These alterations were
mainly located in exons 8 and 9. The mutations in exon 8
included an insertion of FF at codon 419 (InsFF419, one case
(2%)), a single deletion of D419 (D419, eight cases (16%)), a
2-bp deletion with a 1-bp substitution between codons 417
and 419 (D417418D419Y, one case (2%)), and a substitution of
a cysteine at codon 443 with a tyrosine (C443Y, one case
(2%)) (Tables 1 and 2 and Figure 1). In exon 9, there was a
substitution of a serine at codon 476 with an isoleucine (S476I,
one case (2%)), an internal tandem duplication of the
A502Y503 pair (ITD502–503, two cases (4%)), and two other
internal tandem duplications leading to insertions near these
two residues at codons 501 and 505 (ITD501502 and
ITD505508, three cases (6%)). In addition, we identified five
cases (10%) that had K509I substitutions. The C443Y and S476I
mutations are new substitutions that lie nearby and between
hot spots at codons 417–419 and 501–509. Furthermore, in
14 patients (28%), we found a single type of substitution at
codon 541 (M541L), which lies in exon 10. This KIT
polymorphism was reported in mastocytosis and in the
normal population and seems to enhance the response to
only low levels of SCF (Foster et al., 2008). Interestingly, none
Table 1. Continued
c-KIT sequence–RNA1
No. Sex
Type of skin
lesion
Age at
onset
Age at
biopsy
Serum tryptase
(ngml1)
Familial
case Mutation Exon
Exon 10
sequence c-KIT sequence–DNA2
E003 M NA 3 years 10 years ND No D572A 11 M541L ND
E037 M UP 4 years 12 years ND No WT — WT ND
E042 M UP 3 years 13 years ND No WT — WT ND
E043 F UP 3 years 4 years ND Yes WT — WT ND
E060 F MC Birth 3 years ND No WT — WT ND
E048 M NA Birth 1 years ND No WT — WT ND
M123 M NA 2 years 8 years ND Yes WT — WT ND
M216 F NA 3 years 11 years ND No WT — WT ND
DCM, diffuse cutaneous mastocytosis; F, female, M, male; MC, mastocytoma; UP, urticaria pigmentosa; WT, wild type.
1The presence of mutations was assessed by reverse transcription–PCR using RNA isolated from skin biopsies, and the mutations are detailed in Table 2.
2The presence of mutations was assessed by PCR using DNA isolated from blood samples.
3Patient diagnosed with systemic mastocytosis as indicated by bone marrow and liver involvement.
4Patient 017 was first diagnosed with a mastocytoma at 3 months and then with UP at 12 months.
The table includes the 50 patients on whom mutation screening was carried out.
ND indicates not done (that is, blood sample was not available); NA, skin involvement unknown because the case report form was not available.
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of the patients with the wild-type codon 816 sequence
(aspartate) carried the M541L substitution. To assess whether
the M541L mutation was located on the same allele as the
c-KIT D816V mutation, we further genotyped 11 of 14
M541L-positive patients. We found no difference in the
frequency of expression of M541L in the allele bearing the
activating mutations (5 of 11) versus that in the wild-type
allele (6 of 11). We did not find clinical differences between
both groups, but one child among the five of the former group
had diffuse cutaneous mastocytosis. Eventually, we per-
formed sequence analysis for the entire c-KIT coding region
for all patients. Surprisingly, all the newly identified muta-
tions were mutually exclusive of mutations in codon 816
(data not shown). Overall, 43 of the 50 patients (86%) in this
study had mutations in c-KIT.
Analysis of genomic DNA for c-KIT mutations
Blood samples were available for 13 patients, making it
possible to analyze genomic DNA for the presence of c-KIT
mutations. One of these 13 samples was from a patient
(M084) with a familial form of mastocytosis. Mutations in
c-KIT were not found in any of these samples (Table 1),
indicating that in these cases the mutations were somatic
rather than germline.
Ig1
PCR
products 1s – 771r 729s – 1266r
1197s – 2100r 1934s – 2498r 2413s – 2972r
21201918171615141312111098654321
H GNNK isoform
Ig2 Ig3 Ig4 Ig5
TM JM TK1 TK2
7
Δ417–418 D419Y
Δ419 (7)
InsFF419
C443Y
S476I
ITD501-502(2)
ITD502-503(2)
ITD505-508
K509I(5)
M541L(14)
D572A
D816Y(2)
D816I
D816V(18)
Figure 1. Summary of c-KIT mutations found in the patients with childhood mastocytosis. Schematic diagram of the KIT receptor protein and the corresponding
location of the 21-exon coding sequence. The exon numbers are shown in boxes, and specific mutations are indicated in the corresponding regions. The
numbers of identical mutations found in this study appear in parentheses. Also shown is a schematic map of PCR products (primers used are listed in
Supplementary Table 1). The position of GNNKþ isoform is indicated at the end of exon 9. Ig, Ig loop-like domain; JM, juxtamembrane intracellular domain;
TK1 and TK2, tyrosine kinase domain regions 1 and 2, respectively; TM, transmembrane domain.
Table 2. Summary of c-KIT mutations found in this study
Mutation Nucleotide sequence (50-30)1 Position2 Changes in amino acid sequence
D816V agagTcatc 2247 Asp816 to Val
D816Y agaTacatc 2446 Asp816 to Tyr
D816I agaATcatc 2446 Asp816 to Ile
InsFF419 acttacTTCTTCgac agg 1255 Insertion of PhePhe at amino acid 419
D417–419insY gaaatcctg — — Tacaggctc 1249 Replacement of Thr417Tyr418Asp419 with Tyr
D419 acttac — aggctc 1255 Deletion of Asp419
C443Y ttttAtcca 1328 Cys443 to Tyr
S476I cagaTttct 1427 Ser476 to Ile
ITD501502 acttctgcTTCTGcctatttt 1500 Duplication of Ser501Ala
ITD501502 acttctgcctCTGcCtatttt 1502 Duplication of Ser501Ala
ITD502503 tctgcctatGCCTATtttaac 1504 Duplication of Ala502 Tyr
ITD505508 tattttaactttgcatttAACTTTGCATTTaaagag 1525 Duplication of Asn505PheAlaPhe
K509I tttaTagag 1526 Lys509 to Ile
D572A atagCccca 1715 Asp572 to Ala
M541L gtgCtgatt 1621 Met541 to Leu
1Altered sequences are indicated in capital letters.
2Nucleotide positions are indicated according to the c-KIT sequence in GenBank (accession number X06182).
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Effect of mutations on KIT activity in Cos cells
Activation of KIT by the D816V mutation is frequently found
in adult mastocytosis (Buttner et al., 1998). We therefore
examined whether the mutations identified in this study also
caused ligand-independent activation of KIT. Cos cells were
transiently transfected with plasmids expressing wild-type KIT
or KIT containing the D417418D419Y, C443Y, S476I,
ITD502–503, K509I, D572A, D816V, D816Y, or D816I mutation.
After treatment of cells with or without 250 ng ml1 SCF, the
tyrosine phosphorylation of KIT was assessed by western
blotting. As shown in Figure 2, SCF stimulated the tyrosine
phosphorylation of wild-type KIT, and, as expected, the
D816V mutation constitutively activated KIT tyrosine phos-
phorylation. Importantly, all the other tested mutations
resulted in a ligand-independent tyrosine phosphorylation
of KIT (Supplementary Figure 1), except for the M541L variant
(Supplementary Figure 2).
Expression ratio of the GNNKþ and GNNK isoforms in patients
The GNNK (short (S)) and GNNKþ (long (L)) isoforms of KIT
have been shown to signal through different pathways and to
have distinct transforming activities (Caruana et al., 1999);
moreover, deregulation of the expression ratio of these
isoforms may participate in mastocytosis. Therefore, we
examined the expression ratio of the GNNK and GNNKþ
isoforms (S/L ratio). This analysis was performed for 47
patients. In cases in which patients had an insertion or
deletion mutation, both short and long wild-type and mutant
isoforms could be detected, allowing a direct assessment of
the effect of the mutation on mRNA splicing. There was little
or no difference in the S/L ratios for the wild-type or mutant-
length isoforms for these patients (Table 3). It was not possible
to calculate the S/L ratios for patient E041, who had a
12-nucleotide ITD that caused the short mutated isoform to
be the same length as the wild-type long form. For patients
with point mutations in c-KIT, the lengths of the isoforms
were the same as those of the wild type. The mean S/L ratio
for the entire population was 10.8±2.8 (n¼47), and the S/L
ratio for patients with an insertion or deletion mutant of c-KIT
was not significantly different for patients with wild-type KIT
(9.1±3.8 (n¼ 13) vs. 10.2±3.4 (n¼7)).
Genotype–phenotype correlation and comparison of familial
versus sporadic cases
Analysis of genotype–phenotype relationships was possible in
44 cases (Table 4). There was no clear correlation between
the phenotypes (cutaneous involvement) and the genotypes
of the patients, except for an absence of mutations in codon
816 in children whose mastocytosis occurred between the
ages of 3 and 16 years (data not shown). Also, for 48 cases,
we had information on whether the disease was familial or
sporadic. Again, there was no clear correlation between the
genotype and familial versus sporadic disease, except for an
absence of exon 8, 9, and 11 mutations in patients with a
familial form of the disease. Meaningful statistical analysis by
phenotype or familial versus sporadic disease was not
possible because of insufficient numbers of patients in several
of the categories. In addition, none of the patients had an
aggressive form or a tryptase level above 200mg l1.
DISCUSSION
We performed a multicenter study to examine the association
of c-KIT mutations with childhood-onset mastocytosis.
Sequencing of c-KIT was performed in 50 children between
0 and 16 years of age. This was the largest study of mutations
in childhood-onset mastocytosis to date.
We found the D816V mutation (exon 17), which is
frequently associated with adult mastocytosis (Longley
et al., 2001), in 18 of 50 (36%) children in this study. Three
additional patients (6%) had other mutations in codon 816,
including two with a D816Y mutation and one with a
previously unreported D816I mutation. As with the D816V
mutation, we found that both the D816Y and D816I mutations
cause a ligand-independent activation of KIT.
We also identified several genetic alterations in c-KIT in
our patient population, some of which have not previously
been identified in childhood or adult mastocytosis. These
alterations were located mainly in exons 8 and 9 (22 of 50
patients (44%); Figure 1), which encode the fifth Ig (D5)
domain and the extracellular region near the transmembrane
domain, regions that have previously been shown to be
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Figure 2. Ligand-independent autophosphorylation of KIT. Cos cells were
transiently transfected with pcDNA plasmids for expressing wild type or
mutants of KIT and treated with (þ ) or without () 250 ng ml1 stem cell
factor (SCF). Western blotting was carried out using an antibody against KIT
phosphorylated on Tyr719 (anti-PY719 KIT) or with an anti-c-KIT antibody
(anti-KIT).
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Table 3. Expression of GNNK isoforms and S/L ratios
Area under the curve
Wild-type size Mutated size S/L ratio
Patient Genotype GNNK GNNK+ GNNK GNNK+ Wild-type size Mutated size
E001 D816V 69795 5507 0 0 13 NA
E015 D816V 66707 7841 0 0 9 NA
E033 D816V ND ND ND ND ND ND
E047 D816V 66526 5973 0 0 11 NA
E009 D816V 67032 8706 0 0 8 NA
E012 D816V 70751 8826 0 0 8 NA
E024 D816V 69836 5905 0 0 12 NA
E025 D816V 64939 4957 0 0 13 NA
E027 D816V 69350 5509 0 0 13 NA
E031 D816V 66869 4732 0 0 14 NA
E034 D816V ND ND ND ND ND ND
E035 D816V 72160 5464 0 0 13 NA
E036 D816V 69483 8044 0 0 9 NA
E049 D816V 68531 5819 0 0 12 NA
E004 D816V 68904 10487 0 0 7 NA
M081 D816V 65330 5106 0 0 13 NA
M084 D816V 60394 5212 0 0 12 NA
E006 D816V 67922 5577 0 0 12 NA
E018 D816Y 66245 8212 0 0 8 NA
M099 D816Y ND ND ND ND ND ND
E010 D816I 28780 1783 0 0 16 NA
E005 InsFF419 10664 1688 8040 1202 6 7
E008 D419 13733 1016 12833 943 14 14
E050 D419 14727 1089 12829 979 14 13
E022 D419 13266 1803 12213 1717 7 7
E038 D419 67019 7748 57624 7192 9 8
E030 D419 14429 1762 11259 1416 8 8
E026 D419 59224 7741 21743 2692 8 8
E061 D419 12045 1484 12434 1575 8 8
E011 D417419InsY 62184 4197 67474 4863 15 14
E017 C443Y 66178 5882 0 0 11 NA
E032 S476I 73569 6956 0 0 11 NA
E054 ITD501502 14083 938 13226 1519 15 9
E013 ITD501502 13469 1512 11147 1639 9 7
E002 ITD502503 34023 3324 32606 2807 10 12
E020 ITD502503 65419 4268 54359 3144 15 17
E0411 ITD505508 44131 30290 0 0 NC NA
E007 K509I 63898 7419 0 0 9 NA
E014 K509I 50404 4751 0 0 11 NA
E040 K509I 23766 1954 0 0 12 NA
E044 K509I 66224 3909 0 0 17 NA
E053 K509I 65933 6508 0 0 10 NA
Table 3 continued on the following page
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affected in core-binding factor-acute myeloid leukemia and
in GISTs, respectively (Gari et al., 1999; Lux et al., 2000).
Interestingly, alterations in these two exons have been only
rarely found in pediatric or adult forms of mastocytosis. The
mutations in exon 8 included an insertion of FF (InsFF419) and
a single deletion at D419 (D419), as well as a 2-bp deletion
with a 1-bp substitution in the same area (D417418D419Y).
The latter insertion has been reported in core-binding factor-
acute myeloid leukemia (Gari et al., 1999; Goemans et al.,
2005), and the D419 mutation has been identified in kindreds
with familial GISTs and mastocytosis (Hartmann et al., 2005).
In exon 9, there was an internal tandem duplication of the
A502Y503 pair, which has been described mainly in GISTs
(Lux et al., 2000), as well as insertions around these two
residues at codons 501 and 505. In addition, we identified a
substitution in codon 509 (K509I). This mutation was
previously reported in three siblings with familial mastocy-
tosis, but its effect on KIT activity was not examined (Zhang
et al., 2006). Although this is at the 30-limit of exon 9, the
relative ratio of GNNKþ to GNNK isoforms was unchanged
by this mutation, indicating that it did not alter mRNA
splicing. We also identified substitutions C443Y (exon 8) and
S476I (exon 9) for the first time. According to these results, it
seems that there are two hot spots for mutations in childhood-
onset mastocytosis at codons 417–419 and 501–509 (exons 8
and 9, respectively; Figure 1). Substitutions C443Y and S476I
lie near and between these two hot spots.
Interestingly, all the tested mutations in exons 8 and 9
(D417418D419Y, C443Y, S476I, and ITD502–503, and K509I)
activated the tyrosine phosphorylation of KIT. Indeed,
mutations at or near Asp419 and Ala502–Tyr503 are known to
activate KIT, and a very recent crystallographic study
revealed that these residues lie at an interface between D5
domains in the ligand-induced dimers of KIT, suggesting that
oncogenic mutations at these sites act by enhancing
homotypic interactions between D5 domains (Yuzawa
et al., 2007). The activation of KIT by the C443Y mutation
supports the idea that this residue is involved in the proper
folding of the D5 domain (Broudy et al., 2001), so that its
mutation could also enhance the association of D5 domains.
Although the importance of S476 is not currently clear, it
could act in the same manner. Overall, these results strongly
support the idea that residues 417–419 and 501–509 have key
roles in KIT activation, and, furthermore, that they and other
activating mutations in exons 8 and 9 are selectively involved
in childhood-onset mastocytosis.
Surprisingly, we found only one substitution in exon 11
(D572A; patient E003). This residue is part of a peptide
Table 3. Continued
Area under the curve
Wild-type size Mutated size S/L ratio
Patient Genotype GNNK GNNK+ GNNK GNNK+ Wild-type size Mutated size
E003 D572A 66258 7454 0 0 9 NA
E037 Wild type 24654 2719 0 0 9 NA
E042 Wild type 68563 10774 0 0 6 NA
E043 Wild type 68893 7190 0 0 10 NA
E060 Wild type 69413 4040 0 0 17 NA
E048 Wild type 50468 5672 0 0 9 NA
M123 Wild type 57655 9215 0 0 6 NA
M216 Wild type 62026 8657 0 0 7 NA
NA, not applicable; ND, not done.
1NC, not calculable because the short mutated form contained a 12-nucleotide difference, so that it could not be distinguished from the wild-type long
isoform allele.
Table 4. c-KIT mutations by phenotype
Type of skin lesion Familial vs sporadic
Mutation All, n (%) (n=50)
Urticaria pigmentosa,
n (%) (n=31)
Diffuse cutaneous mastocytosis,
n (%) (n=4)
Mastocytoma,
n (%) (n=2)
Familial,
n (%) (n=4)
Sporadic,
n (%) (n=44)
D816V 18 (36) 14 (45) 1 (25) 0 (0) 2 (50) 15 (34)
Any codon 816 21 (42) 15 (48) 2 (50) 0 (0) 2 (50) 18 (41)
Exons 8, 9, or 11 22 (44) 13 (42) 2 (50) 2 (100) 0 (0) 21 (48)
Any mutation 43 (86) 28 (90) 4 (100) 2 (100) 2 (50) 39 (89)
None (wild type) 7 (14) 3 (10) 0 (0) 0 (0) 2 (50) 5 (11)
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sequence that includes Tyr570, which, when phosphorylated,
binds several SH2-domain-containing proteins, such as the
tyrosine phosphatases SHP1 and SHP2 (Kozlowski et al.,
1998), members of the Src family kinases (Lennartsson et al.,
1999), and SOCS6 (Bayle et al., 2004). Thus, this amino acid
could control the recognition of SH2 domains by KIT or
regulate the autoinhibition of its tyrosine kinase activity (Ma
et al., 1999a; Mol et al., 2004). Indeed, we found that,
in vitro, this mutation activated KIT tyrosine phosphorylation.
Several genetic alterations were reported in this peptide
sequence in a large proportion of GISTs (Heinrich et al.,
2003a), as well as in dog mast cell tumors (Longley et al.,
1995), and it has been reported at the analogous site in other
receptor tyrosine kinases, such as in FLT3 in acute myeloid
leukemia (Gilliland and Griffin, 2002) and platelet-derived
growth factor-a receptor in GISTs (Heinrich et al., 2003b).
Although the D572A mutation was found less frequently than
the other c-KIT mutations, it also caused constitutive ligand-
independent autophosphorylation of the KIT protein when
expressed in Cos cells. Importantly, all the identified
extracellular and juxtamembrane intracellular domain muta-
tions are sensitive to imatinib, in contrast to the D816
mutation (Y Yang et al., unpublished data).
Interestingly, we did not detect mutations F522C, V530I, or
A533D, which have been previously identified in mastocytosis
patients and lie in the transmembrane domain of KIT (exon
10) (Akin et al., 2004; O’Brien et al., 2004; Tang et al., 2004).
Because each of these was reported in only a single patient,
they could represent very rare events not appearing in our
panel, or they may be specifically associated with familial
and/or adult mastocytosis.
We found a single substitution at codon 541 (M541L). This
codon lies within exon 10, which encodes the transmem-
brane domain. The Met-to-Leu substitution is conservative,
and because this mutation was previously reported in a
normal population and in normal tissues (Nagata et al.,
1996), it is considered a polymorphic variation. In a recent
article, germline M541L mutations were reported in familial
cases of pediatric mastocytosis. This mutation was shown to
enhance SCF sensitivity slightly (Foster et al., 2008).
However, for one of our M541L-expressing patients, a blood
sample was available, allowing the analysis of genomic
DNA. In this case, the substitution was not present in the
genomic DNA, suggesting that this position may be highly
affected by somatic variation, as previously reported in
patients in the blast crisis of chronic myeloid leukemia
(Inokuchi et al., 2002). In addition, when ectopically
expressed in murine Ba/F3 cells, KIT containing this mutation
mediates cell proliferation to the same extent as the wild-type
receptor, although the mutant seems to be slightly more
sensitive to SCF than the wild-type receptor—but only to low
levels of SCF, as previously reported (Foster et al., 2008)
(Supplementary Figure 2). This M541L mutation could act by
causing a slight change in the conformation of KIT, resulting
in enhanced dimerization and autophosphorylation. In this
way, the M541L mutation could increase cell proliferation in
chronic myeloid leukemia and thereby reduce the survival of
these patients (Inokuchi et al., 2002). In mastocytosis, this
hypersensitivity to SCF could increase the survival of M541L-
expressing mast cells, leading to mast cell accumulation. It is
noteworthy that none of the patients with the wild-type
codon 816 sequence (Asp) carried the M541L substitution.
Importantly, all the tested mutations in codons 8, 9, 11,
and 17 (D417418D419Y, C443Y, S476I, ITD502–503, K509I, D572A,
D816V, D816Y, and D816I) caused a constitutive ligand-
independent activation of KIT, with a higher phosphorylation
status for exon 17 mutations (Figure 2). Combined with the
fact that most (86%) of the patients had mutations in these
codons, this strongly supports the idea that, like adult
mastocytosis, childhood mastocytosis is a clonal disease.
These findings further emphasize the importance of KIT
activation in both pediatric and adult mastocytosis.
Yanagihori et al. (2005) recently described c-KIT muta-
tions in 12 patients with childhood-onset mastocytosis. They
reported that children with a D816F mutation developed
cutaneous mastocytosis at an earlier age than those with the
D816V mutation, although the statistical significance was very
low (P¼ 0.068). In contrast, in this study we did not find any
obvious genotype–phenotype correlations, except for an
absence of mutations in codon 816 in children with an onset
of mastocytosis between 3 and 16 years of age. We also did
not find the D816F mutation in our panel of children with
mastocytosis. The difference between our findings and those
of Yanagihori et al. (2005) may be due to the facts that all of
their patients were of different genetic backgrounds and that
we included a larger number of patients (50 vs 12) in our
study.
This study included four children with a familial form of
the disease. Of these, two had exon 17 (D816V) mutations
without any history of KIT-related tumors (other than
mastocytosis). The other two lacked c-KIT mutations. In
contrast, Longley et al. (1996) did not find exon 17 mutations
in three cases of familial childhood mastocytosis, and,
similarly, Rosbotham et al. (1999) did not find exon 17
mutations in three siblings with familial urticaria pigmentosa.
Furthermore, the four patients in this study with familial
mastocytosis lacked the A533D germline mutation that was
previously reported in a kindred with childhood-onset
familial mastocytosis (Tang et al., 2004), as well as the D419
and K509I mutations, which were originally identified in
kindreds with a combination of familial GISTs and mastocy-
tosis (Hartmann et al., 2005) and with familial mastocytosis
(Zhang et al., 2006), respectively. These four patients also
lacked mutations in exons 8, 9, and 11, although the number
of patients was too low to reliably assess whether there is any
meaningful correlation. In general, these results confirm that
familial childhood-onset mastocytosis can occur both in the
presence and in the absence of c-KIT mutations.
In the 13 patients from whom we could collect blood
samples, we were able to examine genomic DNA for the
presence of c-KIT mutations. Mutations were not found in any
of these cases, suggesting that the mutations are somatic
rather than in the germline. This included one of the patients
with a familial form of mastocytosis, suggesting that it can
arise from causes other than germline mutations in c-KIT.
Interestingly, this was true for several different mutations,
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including in the phosphotransferase and regulatory domains.
This finding supports the idea that, in most cases, childhood
mastocytosis is a clonal disease. Moreover, overall, the
mutations did not seem to cause any changes in mRNA
splicing, as indicated by the S/L ratio, although there was a
less than twofold difference in one case.
We were unable to detect mutations in only 14% (7/50) of
the children in this study. This may be attributable to a lack of
sensitivity of our direct sequencing technique, but previous
studies suggest that it is a result of the absence of genetic
alterations within c-KIT in some mastocytosis patients (Long-
ley et al., 1999; Valent et al., 2003a). This implies that these
patients have alterations in proteins other than KIT that
regulate mast cell proliferation and function.
Collectively, the results reveal that, like adult-onset
mastocytosis, most cases of childhood-onset mastocytosis
are clonal in nature and are associated with activating
mutations in c-KIT. How the pediatric form can sponta-
neously resolve if it is a clonal disease is not clear and is a
major question that remains to be resolved. The under-
standing of this process may open new avenues in the
treatment of adult mastocytosis and may apply in other
cancers as well. In addition, long-term follow-up is needed to
determine whether spontaneous resolution is associated with
particular c-KIT mutations. We propose that c-KIT mutation
analysis should be performed only in clinical trials and in the
few severe cases in which a treatment must be chosen and
targeted therapy could be interesting. Our findings suggest
that, as in adult mastocytosis, KIT could be a good target in
the treatment of pediatric mastocytosis.
MATERIALS AND METHODS
Patients
We assessed patients with childhood-onset cutaneous mastocytosis
in a multicenter clinical study. Mastocytosis was suspected by the
presence of a positive Darier’s sign and was confirmed by
histological analyses. A specific clinical records form was specially
designed for this multicenter study to record the type of mastocy-
tosis, familial history, and results of a complete clinical examination.
For all patients with mastocytosis, the type of skin lesion was
classified as mastocytoma (one to three lesions presenting as red-
brown elevated plaques or nodules), urticaria pigmentosa (red-
brown macules, papules, or nodules with a random distribution), or
diffuse cutaneous mastocytosis (diffuse skin infiltration by mast cells
and increased erythema, with frequent vesicles) (Tharp, 1985; Longley
et al., 1995). When there was evidence of cutaneous and
extracutaneous infiltration by mast cells, patients were diagnosed
with systemic mastocytosis; however, as stipulated by our ethics
committee, extracutaneous biopsies and blood samples could not be
collected unless necessary for treating the patient. Therefore, we
cannot rule out that some cases might have been classified as systemic
if biopsies had been performed. Death was censored. Parents of the
patients in all centers signed the informed-consent and authorization
forms for the study protocol, including genetic analysis, and 2-mm
biopsy samples were collected from a cutaneous lesion after informed
consent had been obtained. This study was approved by the ethics
committee of Hoˆpital Necker and was carried out in compliance with
the Declaration of Helsinki Principles protocol.
Mutation screening
Total RNA was extracted from cutaneous biopsy samples using an
RNeasy Mini Kit (Qiagen S.A., Courtaboeuf, France). RNA was
reverse transcribed into cDNA using a StrataScript first-strand
synthesis system (Stratagene, Massy, France) and random hexamer
primers in a total volume of 25 ml, according to the manufacturer’s
instructions. Next, the c-KIT coding sequence was amplified from
2.5 ml of cDNA by PCR, using HotStarTaq DNA polymerase (Qiagen
S.A.) and the primers listed in Supplementary Table 1 for 40 cycles at
94 1C for 30 seconds, 57 1C for 30 seconds, and 72 1C for 45 seconds.
For the specific detection of mutations at codon 816, primers U2 and
L1 were used. The PCR products were purified using a GeneClean III
KIT (Qbiogene, Illkirch-Graffenstaden, France), and the entire c-KIT
coding region was directly sequenced using a BigDye terminator
v1.1 kit (Applied Biosystems, Courtaboeuf, France), the sequencing
primers listed in Supplementary Table 1, and an ABI Prism 3100
sequencer (Applied Biosystems). Because mast cells are the main
source of c-KIT mRNA in mastocytosis lesions, the presence of both
mutant and wild-type sequences indicates either heterozygosity or a
nonclonal mast cell population in biopsies. The D816V mutation was
also confirmed by PCR amplification of the c-KIT coding sequence
using the fluorescent primers U2F and L1F (see Supplementary Table 1),
followed by restriction digestion using BsmA1 and Ple1, which detect
the wild-type and mutant forms of c-KIT, respectively. The restriction
fragments were separated on an ABI Prism 3100 16-capillary sequencer,
and the size of the restriction fragments was determined by comparison
with the sizes of Genescan ROX 500 markers (Applied Biosystems)
using GeneMapper software (Applied Biosystems).
Determination of the GNNK/GNNKþ isoform (S/L) ratio
Wild-type and mutant isoforms of c-KIT were simultaneously
detected using the LAPP method (Theou et al., 2004) using
fluorescent primers with the following sequences: forward,
50-CCTAGTGTCCAATTCTGACG-30 (corresponding to nucleotides
1176–1195); reverse, 50-CGATTACGAAACCAATCAGCA-30 (corre-
sponding to nucleotides 1594–1574). Fluorescent amplicons were
separated by capillary electrophoresis and identified according to
their size, which was determined by comparison with ILS-600 size
markers (Promega, Madison, WI). The short isoform (GNNK)
produced a 404-bp fragment, and the long isoform (GNNKþ )
produced a 416-bp fragment. The length of the PCR fragment
obtained from the mutated alleles was calculated by adding or
subtracting the number of base pairs inserted or deleted, respec-
tively. The area under the curve for each peak of fluorescence was
determined using GeneMapper software (Applied Biosystems). The
ratio of short to long isoforms (S/L) was calculated for each patient
sample for both wild-type and mutated alleles.
Analysis of genomic DNA
Genomic DNA was purified from blood using the QIAamp DNA
Blood Mini Kit (Qiagen), amplified with intronic primers (see
Supplementary Table 1), and sequenced as described above (see
‘‘Mutation screening’’).
Immunoprecipitation and western blotting
Cos cells were transiently transfected with pcDNA3 plasmids for
expressing human wild-type or mutant c-KIT and treated with or
without 250 ng ml1 SCF (Amgen, Thousand Oaks, CA). Cell lysates
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were prepared as previously described (Ma et al., 1999b). Western
blotting for KIT tyrosine phosphorylation and KIT protein was
performed using an anti-phospho-c-KIT (Tyr719) antibody and a
rabbit anti-human KIT polyclonal antibody (Cell Signaling Techno-
logy, Danvers, MA), respectively.
Statistical analysis
All criteria were analyzed using descriptive statistics, numbers, and
rates for categorical and discontinuous variables, and parametric and
nonparametric distribution elements for continuous variables. The
correlation between phenotypes and genotypes was examined by
comparison of the frequencies using w2-test or Fisher’s exact test and
by comparison of the means using Student’s t-test or the Mann–
Whitney U-test.
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